FDA Grants Ebvallo a Second Look After Agreement With Regulators
Two drugmakers say the FDA has agreed that Ebvallo’s single-arm trial can support a new review for a rare blood cancer, reversing the agency’s earlier finding that the data were insufficient; a late-April meeting with regulators occurred as Vinay Prasad departed the agency, paving a potential path to approval.